VCMCVC Market Cap
Menu

eGenesis valuation, funding and investors

egenesisbio.com ↗LinkedIn ↗

eGenesis works in xenotransplantation solutions development, based in Cambridge, United States. Founded in 2015, it has about 154 employees.

Biotechnology Series D
VALUATION · TODAY
$3.34B −30% after Series D
Range $1.31B – $5.09B · Grade C
TODAY
+12 MO
$2.00B
$4.00B
$6.00B
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Series A $38.0M
Series B $100M
Series C $125M
Series D $191M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY154 employees
+14%6m growth
+12%1y growth
+40%2y growth
100
200
Data from Jan 2021
TODAY
Predicted in 1 yr $2.33B −30% vs today
Predicted next raise $368M if a round comes
Winding-down probability 0%
Last round
Series D · $191M · Sep 2024
Valuation at last round
$2.39B · implied
Headcount
154 · up
Grade
C
Founded
2015
How VCMC values companies →

eGenesis valuation today

VCMC values eGenesis at $3.3B today, with a range of $1.3B to $5.1B and a grade of C. The valuation starts from its last funding round, a Series D round in Sep 2024.

Valuation by date (147 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

eGenesis: valuation by date, as the model would have shown it on each date
DateValuationRangePredicted in 1 yrPhaseHeadcountTrendGradeWinding-down probability
1 Jan 2015$5.25M$1.91M – $14.4M$5.51M (+5%)before first round–unknownD0%
1 Feb 2015$5.28M$1.92M – $14.5M$5.53M (+5%)before first round–unknownD0%
1 Mar 2015$5.29M$1.93M – $14.5M$5.55M (+5%)before first round–unknownD0%
1 Apr 2015$5.32M$1.93M – $14.6M$5.57M (+5%)before first round–unknownD0%
1 May 2015$5.34M$1.94M – $14.7M$5.59M (+5%)before first round–unknownD0%
1 Jun 2015$5.36M$1.95M – $14.7M$5.61M (+5%)before first round–unknownD0%
1 Jul 2015$5.38M$1.96M – $14.8M$5.64M (+5%)before first round–unknownD0%
1 Aug 2015$5.40M$1.97M – $14.8M$5.78M (+7%)before first round–unknownD0%
1 Sep 2015$5.42M$1.97M – $14.9M$5.94M (+10%)before first round–unknownD0%
1 Oct 2015$5.44M$1.98M – $14.9M$6.09M (+12%)before first round–unknownD0%
1 Nov 2015$5.46M$1.99M – $15.0M$6.26M (+15%)before first round–unknownD0%
1 Dec 2015$5.48M$2.00M – $15.1M$6.42M (+17%)before first round–unknownD0%
1 Jan 2016$5.51M$2.00M – $15.1M$6.60M (+20%)before first round–unknownD0%
1 Feb 2016$5.53M$2.01M – $15.2M$6.78M (+23%)before first round–unknownD0%
1 Mar 2016$5.55M$2.02M – $15.2M$6.95M (+25%)before first round–unknownD0%
1 Apr 2016$5.57M$2.03M – $15.3M$7.14M (+28%)before first round–unknownD0%
1 May 2016$5.59M$2.04M – $15.4M$7.33M (+31%)before first round–unknownD0%
1 Jun 2016$5.61M$2.04M – $15.4M$7.53M (+34%)before first round–unknownD0%
1 Jul 2016$5.64M$2.05M – $15.5M$7.72M (+37%)before first round–unknownD0%
1 Aug 2016$5.79M$2.11M – $15.9M$7.93M (+37%)before first round–unknownD0%
1 Sep 2016$5.94M$2.16M – $16.3M$8.15M (+37%)before first round–unknownD0%
1 Oct 2016$6.10M$2.22M – $16.8M$8.36M (+37%)before first round–unknownD0%
1 Nov 2016$6.26M$2.28M – $17.2M$8.59M (+37%)before first round–unknownD0%
1 Dec 2016$6.43M$2.34M – $17.7M$8.81M (+37%)before first round–unknownD0%
1 Jan 2017$6.60M$2.40M – $18.1M$9.05M (+37%)before first round–unknownD0%
1 Feb 2017$6.78M$2.47M – $18.6M$9.29M (+37%)before first round–unknownD0%
1 Mar 2017$6.94M$2.53M – $19.1M$9.52M (+37%)before first round–unknownD0%
17 Mar 2017$211M$139M – $578M$380M (+80%)after a round–unknownC0%
1 Apr 2017$217M$139M – $578M$380M (+75%)after a round–unknownC0%
1 May 2017$227M$139M – $578M$380M (+67%)after a round–unknownC0%
1 Jun 2017$239M$139M – $578M$380M (+59%)after a round–unknownC0%
1 Jul 2017$251M$139M – $578M$380M (+52%)after a round–unknownC0%
1 Aug 2017$264M$139M – $578M$380M (+44%)after a round–unknownC0%
1 Sep 2017$277M$139M – $578M$380M (+37%)after a round–unknownC0%
1 Oct 2017$291M$139M – $578M$380M (+31%)after a round–unknownC0%
1 Nov 2017$306M$139M – $578M$380M (+24%)after a round–unknownC0%
1 Dec 2017$321M$139M – $578M$380M (+18%)after a round–unknownC0%
1 Jan 2018$337M$139M – $578M$380M (+13%)after a round–unknownC0%
1 Feb 2018$354M$139M – $578M$380M (+7%)after a round–unknownC0%
1 Mar 2018$371M$139M – $578M$380M (+2%)after a round–unknownC0%
1 Apr 2018$380M$135M – $578M$380M (0%)after a round–unknownC0%
1 May 2018$380M$129M – $578M$380M (0%)after a round–unknownC0%
1 Jun 2018$380M$122M – $578M$380M (0%)after a round–unknownC0%
1 Jul 2018$380M$116M – $578M$380M (0%)after a round–unknownC0%
1 Aug 2018$380M$111M – $578M$380M (0%)after a round–unknownC0%
1 Sep 2018$380M$105M – $578M$380M (0%)after a round–unknownC0%
1 Oct 2018$380M$100M – $578M$380M (0%)after a round–unknownC0%
1 Nov 2018$380M$95.1M – $578M$380M (0%)after a round–unknownC0%
1 Dec 2018$380M$90.5M – $578M$380M (0%)after a round–unknownC0%
1 Jan 2019$380M$86.0M – $578M$380M (0%)after a round–unknownC0%
1 Feb 2019$380M$81.8M – $578M$380M (0%)after a round–unknownC0%
1 Mar 2019$380M$78.1M – $578M$380M (0%)after a round–unknownD0%
1 Apr 2019$380M$74.2M – $578M$380M (0%)after a round–unknownD0%
1 May 2019$380M$70.6M – $578M$380M (0%)after a round–unknownD0%
1 Jun 2019$380M$67.1M – $578M$380M (0%)after a round–unknownD0%
1 Jul 2019$380M$63.9M – $578M$380M (0%)after a round–unknownD0%
1 Aug 2019$380M$60.7M – $578M$380M (0%)after a round–unknownD0%
1 Sep 2019$380M$57.7M – $578M$380M (0%)after a round–unknownD0%
1 Oct 2019$380M$54.9M – $578M$380M (0%)after a round–unknownD0%
1 Nov 2019$380M$52.2M – $578M$380M (0%)after a round–unknownD0%
8 Nov 2019$689M$485M – $1.5B$1.0B (+50%)after a round–unknownB0%
1 Dec 2019$707M$485M – $1.5B$1.0B (+46%)after a round–unknownB0%
1 Jan 2020$731M$485M – $1.5B$1.0B (+41%)after a round–unknownB0%
1 Feb 2020$757M$485M – $1.5B$1.0B (+36%)after a round–unknownB0%
1 Mar 2020$782M$485M – $1.5B$1.0B (+32%)after a round–unknownB0%
1 Apr 2020$809M$485M – $1.5B$1.0B (+28%)after a round–unknownB0%
1 May 2020$837M$485M – $1.5B$1.0B (+23%)after a round–unknownB0%
1 Jun 2020$866M$485M – $1.5B$1.0B (+19%)after a round–unknownB0%
1 Jul 2020$895M$485M – $1.5B$1.0B (+15%)after a round–unknownB0%
1 Aug 2020$927M$485M – $1.5B$1.0B (+11%)after a round–unknownB0%
1 Sep 2020$959M$485M – $1.5B$1.0B (+8%)after a round–unknownB0%
1 Oct 2020$991M$485M – $1.5B$1.0B (+4%)after a round–unknownB0%
1 Nov 2020$1.0B$485M – $1.5B$1.0B (+1%)after a round–unknownB0%
1 Dec 2020$1.0B$468M – $1.5B$1.0B (0%)after a round–unknownB0%
1 Jan 2021$1.0B$448M – $1.5B$1.0B (0%)after a round52unknownB0%
1 Feb 2021$1.0B$428M – $1.5B$1.0B (0%)after a round52unknownC0%
1 Mar 2021$1.0B$412M – $1.5B$1.0B (0%)after a round52unknownC0%
3 Mar 2021$1.1B$779M – $2.0B$1.4B (+30%)after a round52unknownB0%
1 Apr 2021$1.1B$779M – $2.0B$1.4B (+27%)after a round52unknownB0%
1 May 2021$1.2B$779M – $2.0B$1.4B (+25%)after a round52unknownB0%
1 Jun 2021$1.2B$779M – $2.0B$1.4B (+22%)after a round52unknownB0%
1 Jul 2021$1.2B$779M – $2.0B$1.4B (+19%)after a round52unknownB0%
1 Aug 2021$1.2B$779M – $2.0B$1.4B (+17%)after a round52unknownB0%
1 Sep 2021$1.3B$779M – $2.0B$1.4B (+14%)after a round52unknownB0%
1 Oct 2021$1.3B$779M – $2.0B$1.4B (+12%)after a round52unknownB0%
1 Nov 2021$1.3B$779M – $2.0B$1.4B (+9%)after a round52unknownB0%
1 Dec 2021$1.3B$779M – $2.0B$1.4B (+7%)after a round52unknownB0%
1 Jan 2022$1.4B$779M – $2.0B$1.4B (+4%)after a round52unknownB0%
1 Feb 2022$1.4B$779M – $2.0B$1.4B (+2%)after a round52unknownB0%
1 Mar 2022$1.4B$779M – $2.0B$1.4B (0%)after a round52unknownB0%
1 Apr 2022$1.6B$880M – $2.3B$1.6B (0%)after a round88growingB0%
1 May 2022$1.6B$885M – $2.3B$1.6B (0%)after a round88growingB0%
1 Jun 2022$1.6B$890M – $2.3B$1.6B (0%)after a round88growingB0%
1 Jul 2022$1.6B$895M – $2.3B$1.6B (0%)after a round88growingB0%
1 Aug 2022$1.6B$697M – $2.3B$1.6B (0%)after a round88unknownB0%
1 Sep 2022$1.6B$666M – $2.3B$1.6B (0%)after a round88unknownC0%
1 Oct 2022$1.6B$636M – $2.3B$1.6B (0%)after a round88unknownC0%
1 Nov 2022$1.6B$608M – $2.3B$1.6B (0%)after a round88unknownC0%
1 Dec 2022$1.6B$581M – $2.3B$1.6B (0%)after a round88unknownC0%
1 Jan 2023$1.6B$555M – $2.3B$1.6B (0%)after a round88unknownC0%
1 Feb 2023$1.6B$529M – $2.3B$1.6B (0%)after a round88unknownC0%
1 Mar 2023$1.6B$508M – $2.3B$1.6B (0%)after a round88unknownC0%
1 Apr 2023$1.6B$458M – $2.3B$1.6B (0%)after a round88unknownC0%
1 May 2023$1.7B$708M – $2.4B$1.7B (0%)after a round110upC0%
1 Jun 2023$1.7B$695M – $2.4B$1.7B (-1%)after a round110upC0%
1 Jul 2023$1.7B$682M – $2.4B$1.7B (-1%)after a round110upC0%
1 Aug 2023$1.7B$670M – $2.4B$1.7B (-1%)after a round110upC0%
1 Sep 2023$1.7B$657M – $2.4B$1.7B (-1%)after a round110upC0%
1 Oct 2023$1.7B$356M – $2.4B$1.7B (0%)after a round110unknownC0%
1 Nov 2023$1.0B$329M – $2.3B$741M (-27%)after a round97downC63%
1 Dec 2023$1.0B$313M – $2.3B$724M (-28%)after a round97downC63%
1 Jan 2024$991M$298M – $2.3B$707M (-29%)after a round97downD63%
1 Feb 2024$975M$283M – $2.3B$690M (-29%)after a round97downD63%
1 Mar 2024$976M$270M – $2.3B$689M (-29%)after a round98downD61%
1 Apr 2024$938M$257M – $2.3B$687M (-27%)after a round99downD56%
1 May 2024$946M$245M – $2.3B$699M (-26%)after a round99downD53%
1 Jun 2024$926M$233M – $2.3B$684M (-26%)after a round99downD53%
1 Jul 2024$906M$222M – $2.3B$668M (-26%)after a round99downD53%
1 Aug 2024$951M$216M – $2.4B$712M (-25%)after a round110flatD49%
1 Sep 2024$975M$205M – $2.3B$744M (-24%)after a round110flatD45%
5 Sep 2024$2.4B$1.6B – $4.7B$3.1B (+30%)after a round110flatB0%
1 Oct 2024$2.4B$1.6B – $4.7B$3.1B (+28%)after a round110flatB0%
1 Nov 2024$2.5B$1.6B – $4.7B$3.1B (+25%)after a round110upB0%
1 Dec 2024$2.5B$1.6B – $4.7B$3.1B (+22%)after a round110upB0%
1 Jan 2025$2.6B$1.6B – $4.7B$3.1B (+19%)after a round110upB0%
1 Feb 2025$2.7B$1.6B – $4.7B$3.1B (+17%)after a round110upB0%
1 Mar 2025$2.7B$1.6B – $4.7B$3.1B (+14%)after a round110upB0%
1 Apr 2025$2.8B$1.6B – $4.7B$3.1B (+12%)after a round110upB0%
1 May 2025$2.8B$1.6B – $4.7B$3.1B (+9%)after a round110upB0%
1 Jun 2025$2.9B$1.6B – $4.7B$3.1B (+7%)after a round110upB0%
1 Jul 2025$3.0B$1.6B – $4.7B$3.1B (+5%)after a round110upB0%
1 Aug 2025$3.0B$1.6B – $4.7B$3.1B (+2%)after a round110upB0%
1 Sep 2025$3.2B$1.6B – $4.9B$3.2B (0%)after a round133upB0%
1 Oct 2025$3.3B$1.6B – $5.0B$3.3B (0%)after a round138upB0%
1 Nov 2025$3.3B$1.6B – $5.0B$3.3B (0%)after a round138upB0%
1 Dec 2025$3.2B$1.6B – $4.9B$3.2B (0%)after a round135upB0%
1 Jan 2026$3.2B$1.6B – $4.9B$3.2B (0%)after a round135upB0%
1 Feb 2026$3.2B$1.6B – $4.9B$3.2B (0%)after a round135upB0%
1 Mar 2026$3.2B$1.5B – $4.9B$3.2B (0%)after a round135upB0%
1 Apr 2026$3.2B$1.5B – $4.9B$3.2B (0%)after a round135upB0%
1 May 2026$3.3B$1.5B – $5.0B$3.3B (0%)after a round142upB0%
1 Jun 2026$3.3B$1.1B – $5.0B$3.3B (0%)after a round142flatC0%
1 Jul 2026$3.3B$1.1B – $5.0B$3.3B (0%)after a round142flatC0%
1 Aug 2026$3.3B$1.5B – $5.1B$3.3B (0%)after a round153upC0%
1 Sep 2026$3.3B$1.5B – $5.1B$3.3B (0%)after a round153upC0%
1 Oct 2026$3.3B$1.3B – $5.1B$3.3B (0%)after a round154upC0%
24 Oct 2026$3.3B$1.3B – $5.1B$2.3B (-30%)after a round154upC0%

Key facts about eGenesis

Founded
2015
Headquarters
Cambridge, United States
Employees
about 154 +12% in a year
Total raised
$454M
Funding rounds
4
Last round
Series D Sep 2024

eGenesis was founded in 2015 by George Church and Luhan Yang.

eGenesis funding history

eGenesis has 4 funding rounds on record, from Mar 2017 to Sep 2024, $454M in total. None disclosed a valuation.

  1. Series D 4 Sep 2024

    Led by Lux Capital; with ARCH Venture Partners, Khosla Ventures, Farallon, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation.

    Sources: egenesisbio.com, insideprecisionmedicine.com, clinicaltrialvanguard.com and 5 more

    $191M

  2. Series C 2 Mar 2021

    Led by Samsara BioCapital; with Farallon, Polaris Partners, HBM Healthcare Investments, Invus, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis Capital Management, Altium Capital Management, Monashee Investment Management, Osage University Partners, Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, Alta Partners.

    Sources: egenesisbio.com, globenewswire.com, globalgenes.org and 7 more

    $125M

  3. Series B 7 Nov 2019

    Led by Fresenius Medical Care Ventures; with Leaps by Bayer, Wellington Partners, ARCH Venture Partners, Biomatics Capital, Alta Partners, Khosla Ventures.

    Sources: egenesisbio.com, genengnews.com, wellington-partners.com and 5 more

    $100M

  4. Series A 16 Mar 2017

    Led by Biomatics Capital, ARCH Venture Partners; with Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings, Uprising, Fan Ventures, T1D Fund.

    Sources: synbiobeta.com, mg21.com

    $38M

eGenesis investors

30 investors have backed eGenesis; ARCH Venture Partners, Fresenius Medical Care Ventures and Biomatics Capital and 2 more led at least one round.

  • ARCH Venture Partners lead, 4 rounds
  • Fresenius Medical Care Ventures lead, 3 rounds
  • Biomatics Capital lead, 2 rounds
  • Lux Capital lead
  • Samsara BioCapital lead
  • Khosla Ventures 4 rounds
  • Leaps by Bayer 3 rounds
  • Alexandria Venture Investments
  • DaVita
  • Fan Ventures
  • Heritage Provider Network
  • Invus
  • Monashee Investment Management
  • NATCO Pharmaceuticals
  • Osage University Partners
  • Parkwood Corporation
  • Uprising

What eGenesis does

eGenesis works in biotechnology, with 13 recorded offerings and customers in healthcare and biotechnology.

eGenesis, Inc. is a United States biotechnology company engaged in the development of human-compatible organs for transplantation, with a focus on xenotransplantation. The company operates a porcine genome engineering platform that utilizes gene editing technologies to create donor animals compatible for human transplantation, with applications in kidney, liver, and heart transplantation. eGenesis also conducts clinical research and development activities related to genetically engineered porcine-derived organs for transplantation.

Description from Veridion's company data.

Products and services

  • Xenotransplantation Solutions Development
  • Porcine Genome Engineering Services
  • Genetic Editing for Organ Compatibility
  • Human-Compatible Organ Engineering
  • Porcine-Derived Kidney Development
  • Xenotransplantable Organ Clinical Trials
  • Organ Failure Treatment Advancement
  • Transplantation Medicine Research
  • Regulatory-Approved Xenotransplantation Product Development
  • Immunologic and Molecular Compatibility Optimization
  • Retroviral Risk Reduction Services
  • Patient Outcome Improvement Services
  • Organ Shortage Solution Development

Markets

  • Healthcare
  • Biotechnology

Technology

  • Porcine Genome Engineering
  • Gene Editing for Xenotransplantation
  • Genetic Editing for Retroviral Risk Reduction
  • Genetic Editing for Immunologic Compatibility
  • Genetic Editing for Molecular Compatibility

Certifications

  • FDA cleared

Business model

  • Business-to-Business
  • Manufacturing

Industry codes (NAICS)

  • 541714 Research and Development in Biotechnology (except Nanobiotechnology) 60% match
  • 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) 40% match

Questions about eGenesis

What is eGenesis worth?

Valuation $3.3B (range $1.3B to $5.1B), as of 24 Oct 2026.

Has eGenesis raised money?

eGenesis has 4 funding rounds on record, from Mar 2017 to Sep 2024, $454M in total. None disclosed a valuation.

Who has invested in eGenesis?

ARCH Venture Partners, Fresenius Medical Care Ventures, Biomatics Capital, Lux Capital, Samsara BioCapital and Alta Partners, and 24 more. Lead investors include ARCH Venture Partners, Fresenius Medical Care Ventures, Biomatics Capital and Lux Capital.

How many people work at eGenesis?

About 154, up 12% over the last year. Headcount grew from 52 in Jan 2021 to 154 in Sep 2026.

What does eGenesis do?

eGenesis works in biotechnology, with 13 recorded offerings and customers in healthcare and biotechnology. Its main offerings are xenotransplantation solutions development, porcine genome engineering services and genetic editing for organ compatibility.

When was eGenesis founded, and where is it based?

eGenesis was founded in 2015 and is based in Cambridge, United States. It has about 154 employees, up 12% over the last year.

How we value companiesReport an issue